CoChat

Augmentation of Bri2 molecular chaperone activity against amyloid-β reduces neurotoxicity in mouse hippocampus in vitro

Chen, Gefei, Andrade-Talavera, Yuniesky, Tambaro, Simone, Leppert, Axel, Nilsson, Harriet E., Zhong, Xueying, Landreh, Michael, Nilsson, Per, Hebert, Hans, Biverstål, Henrik, Fisahn, André, Abelein, Axel, Johansson, Jan · 2020 · Communications Biology
Cited by 61

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Molecular chaperones play important roles in preventing protein misfolding and its potentially harmful consequences. Deterioration of molecular chaperone systems upon ageing are thought to underlie age-related neurodegenerative diseases, and augmenting their activities could have therapeutic potential. The dementia relevant domain BRICHOS from the Bri2 protein shows qualitatively different chaperone activities depending on quaternary structure, and assembly of monomers into high-molecular weight oligomers reduces the ability to prevent neurotoxicity induced by the Alzheimer-associated amyloid-β peptide 1-42 (Aβ42). Here we design a Bri2 BRICHOS mutant (R221E) that forms stable monomers and selectively blocks a main source of toxic species during Aβ42 aggregation. Wild type Bri2 BRICHOS oligomers are partly disassembled into monomers in the presence of the R221E mutant, which leads to potentiated ability to prevent Aβ42 toxicity to neuronal network activity. These results suggest that the activity of endogenous molecular chaperones may be modulated to enhance anti-Aβ42 neurotoxic effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42003-020-0757-z

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 65

  1. Balchin, D., Hayer-Hartl, M. & Hartl, F. U. In vivo aspects of protein folding and quality control. Science 353, aac4354 (2016). · DOI · Paper page
  2. Soti, C. & Csermely, P. Aging and molecular chaperones. Exp. Gerontol. 38, 1037–40 (2003). · DOI · Paper page
  3. Wolff, S., Weissman, J. S. & Dillin, A. Differential scales of protein quality control. Cell 157, 52–64 (2014). · DOI · Paper page
  4. Shorter, J. Engineering therapeutic protein disaggregases. Mol. Biol. Cell 27, 1556–60 (2016). · DOI
  5. Aprile, F. A., Sormanni, P. & Vendruscolo, M. A rational design strategy for the selective activity enhancement of a molecular chaperone toward a target substrate. Biochemistry 54, 5103–12 (2015). · DOI
  6. Lindstedt, P. R. et al. Enhancement of the anti-aggregation activity of a molecular chaperone using a rationally designed post-translational modification. ACS Cent. Sci. 5, 1417–1424(2019). · DOI
  7. Sipe, J. D. et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 23, 209–213 (2016). · DOI · Paper page
  8. Landreh, M. et al. The formation, function and regulation of amyloids: insights from structural biology. J. Intern. Med. 280, 164–76 (2016). · DOI
  9. Ankarcrona, M. et al. Current and future treatment of amyloid diseases. J. Intern. Med. 280, 177–202 (2016). · DOI
  10. Soejitno, A., Tjan, A. & Purwata, T. E. Alzheimer’s disease: lessons learned from amyloidocentric clinical trials. CNS Drugs 29, 487–502 (2015). · DOI
  11. Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608 (2016). · DOI · Paper page
  12. Meisl, G., Michaels, T. C. T., Linse, S. & Knowles, T. P. J. Kinetic analysis of amyloid formation. Methods Mol. Biol. 1779, 181–196 (2018). · doi:10.1007/978-1-4939-7816-8_12
  13. Cohen, S. I. et al. Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl Acad. Sci. USA 110, 9758–63 (2013). · DOI · Paper page
  14. Arosio, P., Vendruscolo, M., Dobson, C. M. & Knowles, T. P. Chemical kinetics for drug discovery to combat protein aggregation diseases. Trends Pharmacol. Sci. 35, 127–35 (2014). · DOI · Paper page
  15. Cohen, S. I. A. et al. A molecular chaperone breaks the catalytic cycle that generates toxic Abeta oligomers. Nat. Struct. Mol. Biol. 22, 207–213 (2015). · DOI · Paper page
  16. Wyatt, A. R., Yerbury, J. J., Ecroyd, H. & Wilson, M. R. Extracellular chaperones and proteostasis. Annu. Rev. Biochem. 82, 295–322 (2013). · DOI · Paper page
  17. Shammas, S. L. et al. Binding of the molecular chaperone alphaB-crystallin to Abeta amyloid fibrils inhibits fibril elongation. Biophys. J. 101, 1681–9 (2011). · DOI · Paper page
  18. Månsson, C. et al. Interaction of the molecular chaperone DNAJB6 with growing amyloid-beta 42 (Abeta42) aggregates leads to sub-stoichiometric inhibition of amyloid formation. J. Biol. Chem. 289, 31066–76 (2014). · DOI · Paper page
  19. Arosio, P. et al. Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation. Nat. Commun. 7, 10948 (2016). · DOI · Paper page
  20. Wilson, M. R. & Zoubeidi, A. Clusterin as a therapeutic target. Expert Opin. Ther. Targets 21, 201–213 (2017). · DOI · Paper page
  21. Bonito-Oliva, A., Barbash, S., Sakmar, T. P. & Graham, W. V. Nucleobindin 1 binds to multiple types of pre-fibrillar amyloid and inhibits fibrillization. Sci. Rep. 7, 42880 (2017). · DOI
  22. Chen, G. et al. Bri2 BRICHOS client specificity and chaperone activity are governed by assembly state. Nat. Commun. 8, 2081 (2017). · DOI · Paper page
  23. Poska, H. et al. Dementia-related Bri2 BRICHOS is a versatile molecular chaperone that efficiently inhibits Abeta42 toxicity in Drosophila. Biochem. J. 473, 3683–3704 (2016). · DOI
  24. Hedlund, J., Johansson, J. & Persson, B. BRICHOS - a superfamily of multidomain proteins with diverse functions. BMC Res. Notes 2, 180 (2009). · DOI
  25. Sanchez-Pulido, L., Devos, D. & Valencia, A. BRICHOS: a conserved domain in proteins associated with dementia, respiratory distress and cancer. Trends Biochem. Sci. 27, 329–32 (2002). · DOI · Paper page
  26. Willander, H. et al. High-resolution structure of a BRICHOS domain and its implications for anti-amyloid chaperone activity on lung surfactant protein C. Proc. Natl Acad. Sci. USA 109, 2325–9 (2012). · DOI
  27. Knight, S. D., Presto, J., Linse, S. & Johansson, J. The BRICHOS domain, amyloid fibril formation, and their relationship. Biochemistry 52, 7523–31 (2013). · DOI
  28. Buxbaum, J. N. & Johansson, J. Transthyretin and BRICHOS: the paradox of amyloidogenic proteins with anti-amyloidogenic activity for Abeta in the central nervous system. Front. Neurosci. 11, 119 (2017). · DOI
  29. Oskarsson, M. E. et al. BRICHOS domain of Bri2 inhibits islet amyloid polypeptide (IAPP) fibril formation and toxicity in human beta cells. Proc. Natl Acad. Sci. USA 115, E2752–E2761 (2018). · DOI
  30. Willander, H. et al. BRICHOS domains efficiently delay fibrillation of amyloid beta-peptide. J. Biol. Chem. 287, 31608–17 (2012). · DOI
  31. Nerelius, C., Gustafsson, M., Nordling, K., Larsson, A. & Johansson, J. Anti-amyloid activity of the C-terminal domain of proSP-C against amyloid beta-peptide and medin. Biochemistry 48, 3778–86 (2009). · DOI
  32. Akiyama, H. et al. Expression of BRI, the normal precursor of the amyloid protein of familial British dementia, in human brain. Acta Neuropathol. 107, 53–8 (2004). · DOI
  33. Del Campo, M. et al. BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer’s disease. Neurobiol. Aging 35, 1596–604 (2014). · DOI
  34. Dolfe, L. et al. The Bri2 and Bri3 BRICHOS Domains Interact Differently with Abeta42 and Alzheimer Amyloid Plaques. J. Alzheimers Dis. Rep. 2, 27–39 (2018). · DOI
  35. Martin, L. et al. Regulated intramembrane proteolysis of Bri2 (Itm2b) by ADAM10 and SPPL2a/SPPL2b. J. Biol. Chem. 283, 1644–52 (2008). · DOI · Paper page
  36. Kronqvist, N. et al. Efficient protein production inspired by how spiders make silk. Nat. Commun. 8, 15504 (2017). · DOI
  37. Sarr, M. et al. A spidroin-derived solubility tag enables controlled aggregation of a designed amyloid protein. FEBS J. 285, 1873–1885 (2018). · DOI
  38. Buzsaki, G. Rhythms of the Brain. (Oxford Univ. Press, Oxford, 2006). · DOI · Paper page
  39. Yamamoto, J., Suh, J., Takeuchi, D. & Tonegawa, S. Successful execution of working memory linked to synchronized high-frequency gamma oscillations. Cell 157, 845–57 (2014). · DOI · Paper page
  40. Ribary, U. et al. Magnetic field tomography of coherent thalamocortical 40-Hz oscillations in humans. Proc. Natl Acad. Sci. USA 88, 11037–41 (1991). · DOI · Paper page
  41. Tambaro, S. et al. Blood-brain and blood-cerebrospinal fluid passage of BRICHOS domains from two molecular chaperones in mice. J. Biol. Chem. 294, 2606–2615 (2019). · DOI
  42. Khurana, R. et al. Mechanism of thioflavin T binding to amyloid fibrils. J. Struct. Biol. 151, 229–38 (2005). · DOI · Paper page
  43. Cohen, S. I. A., Vendruscolo, M., Dobson, C. M. & Knowles, T. P. J. From macroscopic measurements to microscopic mechanisms of protein aggregation. J. Mol. Biol. 421, 160–171 (2012). · DOI · Paper page
  44. Knowles, T. P. J. et al. An analytical solution to the kinetics of breakable filament assembly. Science 326, 1533–1537 (2009). · DOI · Paper page
  45. Cohen, S. I. A. et al. Nucleated polymerization with secondary pathways. I. Time evolution of the principal moments. J. Chem. Phys. 135, 065105 (2011). · DOI · Paper page
  46. Cohen, S. I. A., Vendruscolo, M., Dobson, C. M. & Knowles, T. P. J. Nucleated polymerization with secondary pathways. II. Determination of self-consistent solutions to growth processes described by non-linear master equations. J. Chem. Phys. 135, 065106 (2011). · DOI · Paper page
  47. Limbocker, R. et al. Trodusquemine enhances Abeta42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes. Nat. Commun. 10, 225 (2019). · DOI
  48. Mannini, B. et al. Molecular mechanisms used by chaperones to reduce the toxicity of aberrant protein oligomers. Proc. Natl Acad. Sci. USA 109, 12479–84 (2012). · DOI · Paper page
  49. Walti, M. A. et al. Atomic-resolution structure of a disease-relevant Abeta(1-42) amyloid fibril. Proc. Natl Acad. Sci. USA 113, E4976–84 (2016). · DOI · Paper page
  50. Colvin, M. T. et al. Atomic resolution structure of monomorphic Abeta42 amyloid fibrils. J. Am. Chem. Soc. 138, 9663–74 (2016). · DOI · Paper page
  51. Scheidt, T. et al. Secondary nucleation and elongation occur at different sites on Alzheimer’s amyloid-beta aggregates. Sci. Adv. 5, eaau3112 (2019). · DOI · Paper page
  52. Eisenberg, D. & Jucker, M. The amyloid state of proteins in human diseases. Cell 148, 1188–203 (2012). · DOI · Paper page
  53. Trepel, J., Mollapour, M., Giaccone, G. & Neckers, L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10, 537–49 (2010). · DOI · Paper page
  54. Nagaraj, R. H. et al. Enhancement of chaperone function of alpha-crystallin by methylglyoxal modification. Biochemistry 42, 10746–55 (2003). · DOI
  55. Srinivas, V., Raman, B., Rao, K. S., Ramakrishna, T. & Rao, Ch,M. Structural perturbation and enhancement of the chaperone-like activity of alpha-crystallin by arginine hydrochloride. Protein Sci. 12, 1262–70 (2003). · doi:10.1110/ps.0302003
  56. Bongiovanni, M. N., Aprile, F. A., Sormanni, P. & Vendruscolo, M. A rationally designed Hsp70 variant rescues the aggregation-associated toxicity of human IAPP in cultured pancreatic islet beta-cells. Int. J. Mol. Sci. 19, 1443 (2018). · DOI
  57. Haslbeck, M., Weinkauf, S. & Buchner, J. Small heat shock proteins: simplicity meets complexity. J. Biol. Chem. 294, 2121–2132 (2019). · DOI · Paper page
  58. Lelj-Garolla, B. & Mauk, A. G. Self-association and chaperone activity of Hsp27 are thermally activated. J. Biol. Chem. 281, 8169–74 (2006). · doi:10.1074/jbc.m512553200
  59. Gupta, R. & Srivastava, O. P. Deamidation affects structural and functional properties of human alphaA-crystallin and its oligomerization with alphaB-crystallin. J. Biol. Chem. 279, 44258–69 (2004). · doi:10.1074/jbc.m405648200
  60. Benesch, J. L., Ayoub, M., Robinson, C. V. & Aquilina, J. A. Small heat shock protein activity is regulated by variable oligomeric substructure. J. Biol. Chem. 283, 28513–7 (2008). · DOI
  61. Liu, Z. et al. Mechanistic insights into the switch of alphaB-crystallin chaperone activity and self-multimerization. J. Biol. Chem. 293, 14880–14890 (2018). · DOI
  62. Peschek, J. et al. Regulated structural transitions unleash the chaperone activity of alphaB-crystallin. Proc. Natl Acad. Sci. USA 110, E3780-9 (2013). · DOI · Paper page
  63. Lee, J. T. et al. Enhancement of the chaperone activity of alkyl hydroperoxide reductase C from pseudomonas aeruginosa PAO1 resulting from a point-specific mutation confers heat tolerance in Escherichia coli. Mol. Cells 39, 594–602 (2016). · doi:10.14348/molcells.2016.0042
  64. Abelein, A., Gräslund, A. & Danielsson, J. Zinc as chaperone-mimicking agent for retardation of amyloid β peptide fibril formation. Proc. Natl Acad. S. USA 112, 5407–5412 (2015). · DOI · Paper page
  65. Abelein, A., Jarvet, J., Barth, A., Gräslund, A. & Danielsson, J. Ionic strength modulation of the free energy landscape of Aβ40 peptide fibril formation. J. Am. Chem. Soc. 138, 6893–6902 (2016). · DOI

Cited by

See all 61

Metadata

Authors
Chen, G., Andrade-Talavera, Y., Tambaro, S., Leppert, A., Nilsson, H. E., Zhong, X., Landreh, M., Nilsson, P., Hebert, H., Biverstål, H., Fisahn, A., Abelein, A., & Johansson, J.
Venue
Communications Biology
Published
2020-01-20
Volume
3
Issue
1
ISSN
2399-3642
Cited by
61
References
9
Language
en
Licence
Funders
  • Vetenskapsrådet (2016-01967)
  • VINNOVA (2016-04059)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Augmentation of Bri2 molecular chaperone activity against amyloid-β reduces neurotoxicity in mouse hippocampus in vitro. https://app.cochat.ai/papers/10.1038/s42003-020-0757-z
The paper
Chen, G., Andrade-Talavera, Y., Tambaro, S., Leppert, A., Nilsson, H. E., Zhong, X., Landreh, M., Nilsson, P., Hebert, H., Biverstål, H., Fisahn, A., Abelein, A., & Johansson, J. (2020). Augmentation of Bri2 molecular chaperone activity against amyloid-β reduces neurotoxicity in mouse hippocampus in vitro. Communications Biology. https://doi.org/10.1038/s42003-020-0757-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.